Delivery Order SPE2DB22D2211-SPE2DB25FSDLD
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $11,923.84 for Lupron Depot-Ped 30 mg 3-month kits on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price, non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $5,632.97 to AmerisourceBergen Drug Corp for the supply of Lupron Depot-PED 7.5 mg kits under a firm fixed price contract. The award, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a competitively awarded non-set-aside procurement. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $11,154.18 for Lupron Depot-Ped 11.25 mg (a 3-month supply) on September 3, 2025, with ultimate completion by September 4, 2025. This non-set-aside, competitively awarded contract with firm fixed pricing is funded through the Defense Logistics Agency's Medical Supply Chain and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,911.29 to AmerisourceBergen Drug Corp for the supply of Lupron Depot-Ped 11.25 mg kits. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 26, 2025. The delivery order will be fulfilled from AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Lupron Depot-Ped 15 mg kits valued at $2,609.47. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The contract is scheduled for ultimate completion on September 18, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $14,215.44 for Lupron Depot-Ped 11.25 mg kits on September 8, 2025, with completion scheduled for September 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and was issued by the Defense Logistics Agency's Medical Supply Chain. The award leverages AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $54,633.18 to AmerisourceBergen Drug Corp for Lupron Depot-Ped 11.25 mg 3-month supply on August 21, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 22, 2025, is being fulfilled from the vendor's Conshohocken, Pennsylvania location. The award is non-competitive and falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999...
- The Defense Logistics Agency awarded a delivery order valued at $5,577.09 to AmerisourceBergen Drug Corp for Lupron Depot-Ped 11.25 mg, a three-month supply of leuprolide acetate used in pediatric endocrinology. This firm fixed-price delivery order, awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be sourced from...
- The Defense Logistics Agency awarded a $8,190.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lupron Depot-Ped 15 mg kits on September 16, 2025, with an ultimate completion date of September 17, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $23,165.02 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Lupron Depot-Ped 11.25 mg kits. The contract is unclassified as a set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDLDDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,280.87 for Lupron Depot-PED 30 mg 3-month kits on August 22, 2025, with a completion deadline of August 25, 2025. This firm fixed price contract, which carries no set-aside designation, represents a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The product will be performed and delivered from AmerisourceBergen's Conshohocken, Pennsylvania location. As a child delivery order under the SPE2DX IDC, this award exemplifies AmerisourceBergen's role as a critical pharmaceutical vendor for the Defense Health Agency and broader military healthcare systems. Lupron Depot-PED is a specialty hormone treatment used in pediatric medical applications, reflecting the comprehensive therapeutic range that AmerisourceBergen supplies through its federal contracts. The company's status as a major pharmaceutical distributor and healthcare solutions provider, combined with its demonstrated capability to fulfill diverse medical procurement requirements through open competition, positions it as a key supplier within the DLA's global pharmaceutical support network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.3k | 8/22/25 |